Drug main Lupin on Wednesday introduced the launch of its Favipiravir drug beneath the model identify “Covihalt” for the remedy sufferers with gentle to reasonable COVID-19 signs at Rs 49 per pill in India.
Favipiravir has obtained authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin mentioned in a regulatory submitting.
Its Covihalt dosage energy has been developed conserving in thoughts comfort of administration, it acknowledged, including that the drug is accessible as 200 mg tablets within the type of a strip of 10 tablets, and priced at Rs 49 per pill.
Lupin President – India Region Formulations (IRF) Rajeev Sibal mentioned the corporate believes that it will probably leverage its experience in managing widespread group ailments like tuberculosis to proactively attain sufferers throughout India and guarantee entry to Covihalt by means of its robust distribution community and discipline power.
On August 4, Sun Pharmaceutical Industries had launched Favipiravir beneath the model identify “FluGuard” for the remedy of gentle to reasonable instances of COVID-19, at Rs 35 per pill in India.
Shares of Lupin have been buying and selling 0.32 per cent increased at Rs 943.70 apiece on BSE.
(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)